

42

Name of Journal: World Journal of Stem Cells**Manuscript NO:** 63741**Manuscript Type:** REVIEW

Patient-specific induced pluripotent stem cells as “disease-in-a-dish” models for inherited cardiomyopathies and channelopathies – 15 years of research

IPSCs for inherited cardiomyopathies and channelopathies

Miruna Mihaela Micheu, Ana-Maria Rosca

Match Overview

1	Internet 176 words crawled on 19-Feb-2018 circgenetics.ahajournals.org	2%
2	Internet 88 words crawled on 28-Feb-2020 www.mdpi.com	1%
3	Internet 82 words crawled on 15-Aug-2019 link.springer.com	1%
4	Internet 80 words crawled on 23-Feb-2021 jbiomedsci.biomedcentral.com	1%
5	Internet 79 words hdl.handle.net	1%
6	Internet 64 words crawled on 03-Mar-2021 professional.heart.org	1%
7	Internet 59 words crawled on 03-Nov-2020 academic.oup.com	1%
8	Internet 50 words crawled on 01-Aug-2018 www.nature.com	1%
9	Internet 43 words crawled on 21-Jul-2020 academicfree.org	<1%

Patient-specific induced pluripotent stem cells as "disease-in-a-dish"



ALL

IMAGES

VIDEOS



Add the Give

8,710 Results

Any time ▼

[Patient and Disease-Specific Induced Pluripotent Stem ...](https://pharmrev.aspetjournals.org/content/72/1/320)

<https://pharmrev.aspetjournals.org/content/72/1/320> ▼

Jan 01, 2020 · Human **induced pluripotent stem cells** (iPSCs) have emerged as an effective platform for regenerative therapy, disease modeling, and drug discovery. iPSCs allow for the production of limitless supply of **patient-specific** somatic **cells** that enable advancement in cardiovascular precision medicine. Over the past decade, researchers have developed ...

Cited by: 29**Author:** David T. Paik, Mark Chandy, Joseph ...**Publish Year:** 2020

[Human Induced Pluripotent Stem Cells as a Disease Model ...](https://link.springer.com/article/10.1007/s11807-020-00407-5)

<https://link.springer.com/article/10.1007/s11807-020-00407-5>

Search Toc

[Turn off Hover](#)

Patient-specific induced pluripotent stem cells as "disease-in-a-dish"



ALL

IMAGES

VIDEOS

9,340 Results

Any time ▼

Open links in new tab



Patient and Disease–Specific Induced Pluripotent Stem ...

<https://pharmrev.aspetjournals.org/content/72/1/320> ▼

Jan 01, 2020 · Human **induced pluripotent stem cells** (iPSCs) have emerged as an effective platform for regenerative therapy, disease modeling, and drug discovery. iPSCs allow for the production of limitless supply of **patient**-specific somatic **cells** that enable advancement in cardiovascular precision medicine. Over the past decade, researchers have developed protocols to differentiate iPSCs to ...

Cited by: 30**Author:** David T. Paik, Mark Chandy, Joseph C. Wu**Publish Year:** 2020

Cardiovascular Disease Modeling Using Patient-Specific ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581278>

The generation of **induced pluripotent stem cells** (iPSCs) has opened up a new scientific frontier in medicine. This technology has made it possible to obtain **pluripotent stem cells** from individuals with genetic disorders. Because iPSCs carry the identical genetic anomalies related to those disorders, iPSCs are an ideal platform for medical **research**.

Cited by: 28**Author:** Atsushi Tanaka, Shinsuke Yuasa, Koichi ...**Publish Year:** 2015

Induced Pluripotent Stem Cells: From Product-Focused ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747237>

Tse H-F, Ho JCY, Choi S-W, Lee Y-K, Butler AW, Ng K-M, et al. **Patient-specific induced-pluripotent stem cells**-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome ...

Cited by: 4**Author:** Katherine A Campbell, Andre Terzic, Tim...**Publish Year:** 2015

Human Induced Pluripotent Stem Cells as a Disease Model ...

<https://link.springer.com/article/10.1007/s11897-020-00497-5> ▼

Nov 19, 2020 · Kobayashi J, Yoshida M, Tarui S, Hirata M, Nagai Y, Kasahara S, et al. Directed differentiation of **patient**-specific **induced pluripotent stem cells** identifies the transcriptional repression and epigenetic modification of NKX2-5, HAND1, and NOTCH1 in hypoplastic left heart syndrome. PLoS One. 2014;9:e102796.

Author: Anton Deicher, Timon Seeger, Timon ...**Publish Year:** 2021

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

9,300 Results

Any time ▾

Patient and Disease–Specific Induced Pluripotent Stem ...

<https://pharmrev.aspetjournals.org/content/72/1/320> ▾



Jan 01, 2020 · Human **induced pluripotent stem cells** (iPSCs) have emerged as an effective platform for regenerative therapy, disease modeling, and drug discovery. iPSCs allow for the production of limitless supply of patient-specific somatic **cells** ...

Cited by: 33

Author: David T. Paik, Mark Chandy, Joseph...

Publish Year: 2020

Cardiovascular Disease Modeling Using Patient-Specific ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581278>

The generation of **induced pluripotent stem cells** (iPSCs) has opened up a new scientific frontier in medicine. This technology has made it possible to obtain **pluripotent stem cells** from individuals with...

Cited by: 30

Author: Atsushi Tanaka, Shinsuke Yuasa, Koichi No...

Publish Year: 2015

Induced Pluripotent Stem Cells: From Product-Focused ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747237>

Tse H-F, Ho JCY, Choi S-W, Lee Y-K, Butler AW, Ng K-M, et al. Patient-specific **induced-pluripotent stem cells**-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to ...

Cited by: 4

Author: Katherine A Campbell, Andre Terzic, Timot...

Publish Year: 2015

(PDF) Patient-specific induced pluripotent stem-cell ...

<https://www.researchgate.net/publication/44660786...>

Human **induced pluripotent stem** (iPS) **cells** derived from somatic **cells** hold promise to develop novel patient-specific cell therapies and **research models for inherited** and acquired diseases.

(PDF) Cardiomyopathy in a Dish: Using Human Inducible ...

<https://www.researchgate.net/publication/275717630...>

Patient-specific **induced pluripotent stem-cell-derived models** of LEOPARD syndrome. Nature. 2010;465:808-12. [21] Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, et al. Drug